Objective Several studies have assessed the efficacy of angiotensin receptor blockers (ARBs) on peripheral insulin sensitivity using the euglycemic hyperinsulinemic clamp technique in hypertensive subjects. However, these subjects were mostly non-diabetic, and some studies showed that ARB treatment did not improve insulin sensitivity. Thus, it is still uncertain whether ARBs could improve insulin sensitivity in subjects with hypertension and diabetes. Therefore, we evaluated the effect of olmesartan on peripheral insulin sensitivity in subjects with type 2 diabetes and hypertension using M/I value during the euglycemic-hyperinsulinemic clamp technique. Methods We enrolled 10 Japanese subjects with type 2 diabetes and hypertension who had never taken antihypertensive agents. Their blood pressure, fasting plasma glucose level, HbA1c and glucose utilization rate during euglycemic-hyperinsulinemic clamp (M/I value) were examined before and after 6 months of treatment with 10-20 mg/day olmesartan (mean: 13.0 mg/day). Results Blood pressure decreased significantly from 156/88 mmHg before starting olmesartan to 135/76 mmHg after 6 months of olmesartan treatment. The mean M/I value increased significantly from 6.33±3.19 (mg/kg/min/mU/L) × 100 to 8.11±4.20 (mg/kg/min/mU/L) × 100. Peripheral insulin sensitivity improved in eight out of ten subjects. Fasting glucose levels and HbA1c levels also decreased significantly. Conclusion These results indicate that olmesartan improves glucose metabolism by improving the peripheral insulin sensitivity in subjects with type 2 diabetes.
Introduction
Recent clinical trials, such as the Captopril Primary Prevention Project (CAPPP) (1) , and Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVI-GATOR) (2) , have shown that blockade of the reninangiotensin system (RAS) substantially lowers the risk of developing type 2 diabetes through improved insulin sensitivity. We also have previously shown that angiotensinconverting enzyme inhibitors (ACEIs) could improve insulin sensitivity in subjects with type 2 diabetes (3), and further suggested the possible involvement of RAS and kallikreinkinin system in insulin resistance (4, 5) . Moreover, it is well known that angiotensin II type 1 receptor blockers (ARBs) have organ-protective effects in addition to their antihypertensive effects (6) . Thus, ARBs and ACEIs are now regarded as the first-line treatment for hypertension in patients with type 2 diabetes.
Several studies have evaluated the effects of ARBs on insulin sensitivity using euglycemic-hyperinsulinemic clamps, which is regarded as the 'gold standard' method for estimating peripheral insulin sensitivity (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . In these reports, however, various ARBs were evaluated and their effects on insulin sensitivity were inconsistent. Moreover, except for one study (13) , the subjects were non-diabetic. In some of the studies, the ARB did not improve insulin sensitivity (7, 8, (10) (11) (12) (13) (15) (16) (17) , but it did in others (9, 14, 16, 18, 19) .
Based on these earlier findings, it seems possible that the effects of ARBs on insulin sensitivity varied among agents, and there is currently insufficient evidence to confirm the clinical efficacy of ARBs on peripheral insulin sensitivity in subjects with diabetes.
Therefore, in the present study, we intended to clarify the effect of olmesartan on peripheral insulin sensitivity in subjects with diabetes. To achieve this, we administered olmesartan to subjects with type 2 diabetes and hypertension who had never previously taken antihypertensive agents, and evaluated insulin sensitivity using M/I value during euglycemic-hyperinsulinemic clamps. This is the first report that investigated the effect of olmesartan on peripheral insulin sensitivity in subjects with type 2 diabetes and hypertension using the M/I value.
Materials and Methods

Subjects and study design
The study included 10 hypertensive subjects (office blood pressure ! 140/90 mmHg) with type 2 diabetes who visited our medical institution as outpatients. The subjects included 3 males and 7 females with a mean age of 53.2±11.7 years and mean duration of diabetes of 8.5±6.4 years. Subjects with systolic blood pressure (SBP) <160 mmHg received 10 mg/day olmesartan and those with SBP ! 160 mmHg received 20 mg/day olmesartan. The dosage of olmesartan was not altered until the end of the study. SBP, diastolic blood pressure (DBP), pulse rate, body weight, body mass index (BMI), abdominal circumference, fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), highdensity lipoprotein cholesterol (HDL-C), triglyceride (TG), serum creatinine, HbA1c, insulin resistance index determined by the euglycemic-hyperinsulinemic clamp (M/Ivalue), urinary albumin-creatinine ratio (UACR), highsensitive C-reactive protein (hs-CRP), brachial-ankle pulse wave velocity (baPWV) and total-adiponectin were determined at baseline and after 6 months of treatment. Antidiabetic agents containing insulin, statins or fibrates were not newly administered or their doses were not increased or changed from 3 months before the start of olmesartan to the end of the study. Subjects treated with corticosteroids were excluded from this study. In addition, subjects with secondary hypertension, severe renal disease, severe hepatic disease, overt cardiovascular disease, or malignancy were excluded. The subjects were advised not to alter their lifestyle, including diet, exercise or other habits during the study. All subjects gave written informed consent to participate in the study. The study protocol was approved by the ethics committee of Kumamoto University (approval number 536).
Euglycemic-hyperinsulinemic clamps and laboratory data
The euglycemic-hyperinsulinemic clamp was performed using an artificial endocrine pancreas model STG-22 (Nikkiso, Tokyo) (20) according to the method of DeFronzo et al. (21) . In brief, insulin (Novolin R; Novo Nordisk, Copenhagen, Denmark) was continuously infused at a rate of 1.50 mU/kg/min after the priming insulin infusion during the first 10 minutes of the clamp at the same dose to achieve the desired steady-state plasma insulin level (100 μU/mL). Blood glucose levels were measured every 5 minutes during the 120-min clamp, and euglycemia (90 mg/dL) was maintained by infusion of variable amounts of 20% glucose solution. The total-body glucose disposal rate was determined as the mean glucose infusion rate during the last 30 minutes of the clamp. The M/I value was calculated using the steady-state plasma insulin levels during the last 30 minutes of the clamp to correct for any variations in the plasma insulin level (13, 15, 22) .
Blood samples were obtained between 8:00 and 9:00 after an overnight fast. Plasma insulin levels were measured by an electrochemiluminescent immunoassay (eclusis insulin; Roche Diagnostics, Basel, Switzerland). Total adiponectin was measured by an enzyme immunoassay and hs-CRP was measured by latex nephelometry at a private laboratory (Mitsubishi Chemical Medience Corporation, Tokyo, Japan). (23). LDL-C was measured using a homogenous assay (Deteriner LDL-C; Kyowa Medex, Tokyo, Japan). BaPWV was measured using an automatic waveform analyser (BP-203RPEII, Omron Colin, Tokyo, Japan).
Statistical analysis
Data are expressed as mean ± standard deviation. Changes in clinical parameters following olmesartan treatment were evaluated using paired t-tests. Values of p<0.05 were considered to be statistically significant. Data analyses were performed using SPSS software version 11.5 for Windows (SPSS Inc., Chicago, IL, USA). 
Results
All 10 subjects completed the trial. During the study, no clinically significant adverse events occurred. The baseline characteristics of the subjects are shown in Table 1 . Changes in clinical parameters between baseline and after 6 months of olmesartan treatment are shown in Table 2 . Olmesartan was administered at a dose of 20 mg/day in 3 subjects, and at 10 mg/day in the remaining 7 subjects. SBP decreased significantly from 156±12 mmHg at baseline to 135±11 mmHg after 6 months of treatment. DBP (from 88±8 mmHg to 76±9 mmHg) and FPG (from 135±48 mg/dL to 116±33 mg/dL) also decreased significantly from baseline to the end of the study. On the other hand, no significant changes were observed in pulse rate, body weight, BMI, abdominal circumference, LDL-C, HDL-C, TG or serum creatinine.
In the euglycemic-hyperinsulinemic clamp, 8/10 subjects showed improvements in insulin sensitivity after 6 months of olmesartan treatment. The mean M/I value increased significantly from 6.33±3.19 (mg/kg/min/mU/L) × 100 at baseline to 8.11±4.20 (mg/kg/min/mU/L) × 100 at endpoint (p= 0.02, Figure A) . HbA1c decreased significantly from 7.2± 1.0% to 7.0±1.0% (p=0.03, Figure B ). In the 8 subjects with an increase in the M/I-value, HbA1c decreased in 7 subjects and was unchanged in 1 subject. A significant correlation was not observed between the % change in SBP/DBP and % change in M/I value (calculated as (post-treatment valuebaseline value) × 100/baseline value), and between other parameters (age, duration of diabetes, BMI, antidiabetic agents) and % change in M/I-value. No significant changes were observed for UACR, total-adiponectin or hs-CRP (Table 3, Figure C) . BaPWV decreased significantly from 1,911±563 cm/s to 1,672±482 cm/s.
Discussion
The molecular crosstalk between the insulin signalling pathway and the renin-angiotensin-aldosterone system has been reported. It is known that chronic administration of angiotensin II (AngII) to animal models of diabetes reduces skeletal muscle glucose uptake (24) , from which it can be inferred that ARBs have a latent insulin sensitivityimproving activity. In addition, several mechanisms have been proposed to explain how ARBs may improve insulin sensitivity (25) . The most likely mechanism seems to be an attenuation of the effects of AngII on the intracellular insulin signalling pathway. In an in vitro study using rat aortic smooth muscle cells, it was reported that AngII inhibited insulin signalling at multiple stages, including accelerating serine phosphorylation of insulin receptor substrate-1 (IRS-1) and serine phosphorylation of phosphatidylinositol-3-kinase (PIK3K) (26) . In diabetic KK-Ay mice, administration of an ARB increased insulin sensitivity and glucose uptake in skeletal muscle by stimulating the insulin signalling cascade and consequently it enhanced glucose transporter type 4 (GLUT4) translocation to the plasma membrane (27) . Based on these results in animal models of type 2 diabetes, it seems likely that ARBs would also improve insulin sensitivity in subjects with type 2 diabetes. However, the effects of ARBs on insulin sensitivity in humans remain controversial, due to the inconsistent results of clinical studies using euglycemic-hyperinsulinemic clamps performed to date (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Twelve studies have evaluated the effects of ARBs on insulin sensitivity in non-diabetic subjects using euglycemichyperinsulinemic clamp (7) (8) (9) (10) (11) (12) (13) (14) (15) (17) (18) (19) . Among them, four studies [1 out of 7 studies on losartan (9), 1 out of 3 on candesartan (14), 1 out of 1 on telmisartan (18) 0.14 0.33 0.01 0.31 Data are means ± SD. UACR: urinary albumin-creatinine ratio, hs-CRP: high sensitive C-reactive protein, baPWV: brachial-ankle pulse wave velocity on valsartan (19)] showed significant improvements in insulin sensitivity, and the other studies did not find significant improvement. Thus, to date, clinical trials of ARBs have reported either an increase or no effect on insulin sensitivity determined by euglycemic-hyperinsulinemic clamps in nondiabetic subjects. Therefore, the effects of ARBs on peripheral insulin sensitivity in non-diabetic subjects remain controversial. Regarding losartan, which was examined in most of the studies, the majority of reports concluded that losartan does not improve insulin sensitivity (7, 8, (10) (11) (12) (13) . Taking into consideration the results of these clinical studies, we think that the effect of olmesartan on insulin sensitivity may not be a class effect of ARB and the clinical efficacy of ARBs on insulin sensitivity may vary among different ARBs. Overall, the inconsistent findings of these earlier reports suggest that the effects of ARBs on insulin sensitivity might be influenced by various conditions, including the dosage, duration of treatment, blood pressure, basal conditions of the subjects and other unknown factors.
On the other hand, we have found only one study that evaluated the effects of ARB on insulin sensitivity using euglycemic-hyperinsulinemic clamp in diabetic subjects (16) . In the study, Derosa et al. (16) treated hypertensive subjects with type 2 diabetes with either 16 mg/day candesartan or 20 mg/day olmesartan for 1 year. They reported that the glucose infusion rate during the euglycemichyperinsulinemic clamp increased in subjects treated with candesartan, but not in subjects treated with olmesartan. Thus, they concluded that candesartan, but not olmesartan, affected adipose tissue metabolism, because candesartan significantly increased serum adiponectin levels in the subjects.
However, our results differ from their findings. In their study, the insulin infusion rate during the clamp was 1.0 mU/kg/min, which was lower than the usual infusion rate (1.12-1.50 mU/kg/min) (20); thus, it is possible that the plasma insulin levels during the clamp did not reach the target plasma insulin levels (100 μU/mL). Furthermore, they evaluated insulin sensitivity based on glucose infusion rate, rather than the insulin sensitivity index (M/I-value), which adjusts for variation in insulin levels. Lower plasma insulin levels during a clamp are more likely to result in the underestimation of insulin sensitivity when insulin sensitivity is evaluated based on the glucose infusion rate (22) . In the present study, the plasma insulin level was adjusted to approximately 100 μU/mL and we evaluated insulin sensitivity using the M/I-value. Thus, these methodological differences may explain the differences in results between the present study and the report by Derosa et al. (16) .
Adiponectin and hs-CRP are closely and inversely associated with insulin resistance. Olmesartan did not cause a significant increase in adiponectin concentrations in subjects with chronic kidney disease (CKD) (28) . It was also reported that telmisartan is a partial peroxisome proliferatoractivated receptor (PPAR) γ agonist (29) and PPARγ agonists increase adiponectin secretion (30) . However, in a study of Nakayama et al., 20 hypertensive subjects with type 2 diabetes were switched from 80 mg/day valsartan to 20 mg/day olmesartan or 40 mg/day telmisartan, but no significant improvement in adiponectin concentration was observed in either group (31). Olmesartan did not affect the total-adiponectin in the present study. In contrast, olmesartan reduced hs-CRP levels in subjects with essential hypertension and hs-CRP >3.0 mg/L (32); a similar change in hs-CRP was not observed in our study. The precise reason for these differences is not clear, but the subjects in the present study had hs-CRP levels <3.0 mg/L and we enrolled a small number of subjects. Since the relationship between insulin sensitivity and inflammatory parameters, as well as metabolic markers, is very important to elucidate the effects of ARBs on insulin sensitivity, we need to investigate this issue in a large number of subjects in future studies.
Overactivity of the RAS is implicated in the deterioration of renal function in diabetic subjects with micro-or macro-albuminuria (33) . In the present study, olmesartan did not alter the UACR in subjects with normoalbuminuria. The UACR showed a decreasing trend after the administration of olmesartan in subjects with micro-or macroalbuminuria, which was not statistically significant.
The subjects in the present study had not previously been treated with any antihypertensive drugs, and their on-going treatments for diabetes and lipid abnormalities were not changed. Furthermore, no significant changes were observed in their body weight, BMI and abdominal circumference during the study. Therefore, olmesartan seems to be responsible for the improvement in insulin sensitivity. The subjects in the present study had relatively mild hypertension, and their blood pressure was normalised by olmesartan. Moreover, olmesartan did slightly but significantly improve HbA1c levels. Thus, olmesartan may improve hypertension and glucose metabolism in hypertensive subjects with type 2 diabetes.
The subjects in the present study had relatively mild hypertension, and their blood pressure was normalised by olmesartan. Moreover, olmesartan did significantly improve HbA1c levels. Thus, olmesartan may improve hypertension and glucose metabolism in hypertensive subjects with type 2 diabetes.
Our study design had several limitations, including the absence of a control group to serve as a benchmark for some of the safety and efficacy endpoints. Therefore, future research needs to investigate the effects of olmesartan on insulin sensitivity in a large number of subjects and over a long experimental period.
In conclusion, olmesartan, an ARB, is an antihypertensive agent that has beneficial effects on glucose metabolism by improving peripheral insulin sensitivity without changing BMI and abdominal circumference in hypertensive subjects with type 2 diabetes.
